R B Fiets1,2, J M Bos3, Art Donders4, M Bruns5, Ejp Lamfers6, J A Schouten5, C Kramers2,3,7. 1. Department of General Internal Medicine, Canisius Wilhemina Hospital, Nijmegen, Nijmegen, The Netherlands. 2. Department of General Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. 3. Department of Hospital Pharmacy, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands. 4. Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands. 5. Department of Intensive Care, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands. 6. Department of Cardiology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands. 7. Department of Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands.
Abstract
BACKGROUND: High-dose erythromycin used as antibiotic prolongs QTc interval. Low-dose erythromycin is frequently used as a prokinetic agent, especially in patients in the intensive care unit (ICU). It is unknown whether low-dose erythromycin affects cardiac repolarisation and puts patients at risk for torsades de pointes. METHODS: In this prospective study, we included ICU patients treated with erythromycin as prokinetic in a dose of 200 mg twice a day. An ECG was performed before, 15 min and 24 hours after the start of erythromycin. Cardiac repolarisation was assessed by rate-corrected analysis of the QT interval (QTc) on the ECG by two independent investigators. Starting or stopping other possibly QTc prolonging drugs during the study period was an exclusion criterion. Wilcoxon signed-rank test and Friedman's test were used for statistical analysis to assess prolongation of QTc. Primary outcome was defined by the prolongation of QTc after 15 min and 24 hours. RESULTS: 51 patients were eligible for this study. In these patients, QTc increased significantly from 430 ms at baseline to 439 ms (p=0.03) after 15 min and 444 ms (p=0.01) after 24 hours. After 15 min and 24 hours, the upper limit of 95% CI for prolongation of QTc was well above 10 ms. No QTc-related arrhythmias were seen. CONCLUSIONS: During treatment with erythromycin in a dose of 200 mg twice a day. QTc prolonged mildly but significantly. Sequential ECG registration should be performed when low-dose erythromycin is prescribed, especially in the presence of other risk factor for QTc prolongation.
BACKGROUND: High-dose erythromycin used as antibiotic prolongs QTc interval. Low-dose erythromycin is frequently used as a prokinetic agent, especially in patients in the intensive care unit (ICU). It is unknown whether low-dose erythromycin affects cardiac repolarisation and puts patients at risk for torsades de pointes. METHODS: In this prospective study, we included ICU patients treated with erythromycin as prokinetic in a dose of 200 mg twice a day. An ECG was performed before, 15 min and 24 hours after the start of erythromycin. Cardiac repolarisation was assessed by rate-corrected analysis of the QT interval (QTc) on the ECG by two independent investigators. Starting or stopping other possibly QTc prolonging drugs during the study period was an exclusion criterion. Wilcoxon signed-rank test and Friedman's test were used for statistical analysis to assess prolongation of QTc. Primary outcome was defined by the prolongation of QTc after 15 min and 24 hours. RESULTS: 51 patients were eligible for this study. In these patients, QTc increased significantly from 430 ms at baseline to 439 ms (p=0.03) after 15 min and 444 ms (p=0.01) after 24 hours. After 15 min and 24 hours, the upper limit of 95% CI for prolongation of QTc was well above 10 ms. No QTc-related arrhythmias were seen. CONCLUSIONS: During treatment with erythromycin in a dose of 200 mg twice a day. QTc prolonged mildly but significantly. Sequential ECG registration should be performed when low-dose erythromycin is prescribed, especially in the presence of other risk factor for QTc prolongation.
Authors: Sami Viskin; Uri Rosovski; Andrew J Sands; Edmond Chen; Peter M Kistler; Jonathan M Kalman; Laura Rodriguez Chavez; Pedro Iturralde Torres; Fernando E S Cruz F; Osmar A Centurión; Akira Fujiki; Philippe Maury; Xiaomin Chen; Andrew D Krahn; Franz Roithinger; Li Zhang; G Michael Vincent; David Zeltser Journal: Heart Rhythm Date: 2005-06 Impact factor: 6.343
Authors: Nam Q Nguyen; Marianne J Chapman; Robert J Fraser; Laura K Bryant; Richard H Holloway Journal: Crit Care Med Date: 2007-02 Impact factor: 7.598
Authors: Marc A Ritz; Marianne J Chapman; Robert J Fraser; Mark E Finnis; Ross N Butler; Patricia Cmielewski; Geoffrey P Davidson; Deborah Rea Journal: Intensive Care Med Date: 2005-06-07 Impact factor: 17.440
Authors: Nam Q Nguyen; Marianne Chapman; Robert J Fraser; Laura K Bryant; Carly Burgstad; Richard H Holloway Journal: Crit Care Med Date: 2007-11 Impact factor: 7.598
Authors: Wayne A Ray; Katherine T Murray; Sarah Meredith; Sukumar Suguna Narasimhulu; Kathi Hall; C Michael Stein Journal: N Engl J Med Date: 2004-09-09 Impact factor: 91.245
Authors: Scott J C Stanat; Carol G Carlton; William J Crumb; Krishna C Agrawal; Craig W Clarkson Journal: Mol Cell Biochem Date: 2003-12 Impact factor: 3.396
Authors: Tien Mh Ng; Adrienne M Bell; Chandra Hong; Jill M Hara; Daniel R Touchette; Karine N Danskey; Tanya T Lindsay; Susan E Puumala Journal: Ann Pharmacother Date: 2008-03-04 Impact factor: 3.154
Authors: Florine A Berger; Willem van Weteringen; Heleen van der Sijs; Nicole G M Hunfeld; Jeroen J H Bunge; Natasja M S de Groot; Patricia M L A van den Bemt; Teun van Gelder Journal: Pharmacol Res Perspect Date: 2021-12